Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02194738 · ClinicalTrials.gov registry record · NA
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
A NA study of Stage IIIB Lung Cancer AJCC v8 and Stage IIIA Lung Cancer AJCC v8, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- NA
- Development phase
- 8,300
- Enrollment target
- 20
- Study locations
NCT02194738 is a NA study of Stage IIIB Lung Cancer AJCC v8 and Stage IIIA Lung Cancer AJCC v8 that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 8,300 participants, above the 183-participant average among 31 other Stage IIIB Lung Cancer AJCC v8 trials with a reported enrollment target (4436% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT02194738, a NA study of Stage IIIB Lung Cancer AJCC v8 and Stage IIIA Lung Cancer AJCC v8, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 8,300 participants
- Enrollment target
- 20
- Study locations
Study Summary
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Conditions Studied
Interventions
- DRUG Carboplatin
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- DRUG Cisplatin
- OTHER Clinical Observation
Study Locations (20)
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Anchorage Radiation Therapy Center - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Regional Hospital - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
- Fairbanks Memorial Hospital - Fairbanks
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
- Southern Cancer Center PC-Daphne - Daphne
- Southern Cancer Center PC-Mobile - Mobile
- Southern Cancer Center PC-Providence - Mobile
- Southern Cancer Center PC-Springhill - Mobile
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Kingman Regional Medical Center - Kingman
- Cancer Center at Saint Joseph's - Phoenix
- Banner-University Medical Center Phoenix - Phoenix
- Mayo Clinic Hospital in Arizona - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,300 participants |
| Start Date | 2014-09-26 |
| Est. Completion | 2026-09-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02194738
The ClinicalTrials.gov registry entry for NCT02194738 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 8,300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 183-participant average among 31 other Stage IIIB Lung Cancer AJCC v8 trials with a reported enrollment target (4436% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Stage IIIB Lung Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT02194738 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Alaska, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT02194738 about?
NCT02194738 is a clinical study titled "Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)". This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
What is the current status of trial NCT02194738?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 8,300 participants. The study started on 2014-09-26. Estimated completion is 2026-09-28.
What conditions does trial NCT02194738 study?
This clinical trial studies the following conditions: Stage IIIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7.
What interventions are being tested in trial NCT02194738?
The interventions under investigation include: Carboplatin (DRUG), Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Cisplatin (DRUG), Clinical Observation (OTHER).
Who is sponsoring clinical trial NCT02194738?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02194738 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IIIB Lung Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Model Based Personalized Chemoradiation
RECRUITING · NA
-
Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer
RECRUITING · NA
-
A Nurse-Led Intervention for Fear of Progression in Advanced Cancer
ACTIVE NOT RECRUITING · NA
-
Conquer Fear SUPPORT Intervention in Supporting Patients With Stage III-IV Lung or Gynecologic Cancer
COMPLETED · NA
-
Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
RECRUITING · Phase 2
-
Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.